T1132 Pharmacokinetics and Exposure-Response Relationship of Ustekinumab, a Human Monoclonal Antibody to Interleukin 12/23, in Patients with Moderate-to-Severe Crohn's Disease

2008 ◽  
Vol 134 (4) ◽  
pp. A-490 ◽  
Author(s):  
Adedigbo A. Fasanmade ◽  
Omoniyi J. Adedokun ◽  
Jewel R. Johanns ◽  
Honghui Zhou ◽  
Hugh M. Davis ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Human Monoclonal Antibody ◽  
Interleukin 12 ◽  
Response Relationship ◽  
Exposure Response ◽  
Relationship Of

scholarly journals Exposure-response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease

2017 ◽  
Vol 47 (2) ◽  
pp. 229-237 ◽  
Author(s):  
N. Vande Casteele ◽  
B. G. Feagan ◽  
S. Vermeire ◽  
M. Yassine ◽  
J. Coarse ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Maintenance Therapy ◽  
Certolizumab Pegol ◽  
Response Relationship ◽  
Exposure Response ◽  
Relationship Of

scholarly journals Posterior Reversible Encephalopathy Syndrome following Ustekinumab Induction for Crohn’s Disease

2018 ◽  
Vol 12 (2) ◽  
pp. 521-527 ◽  
Author(s):  
Avantika Mishra ◽  
Darren N. Seril
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Posterior Reversible Encephalopathy Syndrome ◽  
Human Monoclonal Antibody ◽  
Interleukin 12 ◽  
Cytokine Signaling ◽  
Acute Encephalopathy ◽  
Posterior Reversible Encephalopathy ◽  
Inflammatory Bowel ◽  
Reversible Encephalopathy

Biological agents are frequently used in the management of inflammatory bowel disease, and it is important to understand the potential adverse effects of these therapies. Ustekinumab is a human monoclonal antibody that interferes with interleukin-12 and -23 cytokine signaling and is approved for the treatment of moderate to severe Crohn’s disease. We report 2 cases of neurological adverse events, one of which is consistent with posterior reversible encephalopathy syndrome (PRES), in the setting of ustekinumab therapy for Crohn’s disease. The first patient had a seizure and classic neuroimaging features of PRES following induction with ustekinumab. The second patient presented with acute encephalopathy and atypical imaging findings concerning for PRES after ustekinumab induction. Both patients recovered fully following cessation of ustekinumab therapy. PRES associated with ustekinumab is uncommon, but must be a consideration in Crohn’s disease patients receiving this therapy who present with focal neurological symptoms or change in mentation.

Mo1231 Vedolizumab Exposure-Response Relationship During Induction Therapy in Adults With Crohn's Disease

2014 ◽  
Vol 146 (5) ◽  
pp. S-592-S-593 ◽  
Author(s):  
Jonathan French ◽  
Maria Rosario ◽  
Nathanael L. Dirks ◽  
Ashley Milton ◽  
Irving Fox ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Induction Therapy ◽  
Response Relationship ◽  
Exposure Response

Sa1937 Exposure-Response Relationship for Certolizumab Pegol During the Induction Phase in Patients With Crohn's Disease

2016 ◽  
Vol 150 (4) ◽  
pp. S409
Author(s):  
Niels Vande Casteele ◽  
Larry Stitt ◽  
Marshall Spearman ◽  
Gordana Kosutic ◽  
Ruth Oliver ◽  
...  
Keyword(s):  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Certolizumab Pegol ◽  
Induction Phase ◽  
Response Relationship ◽  
Exposure Response
Sign in / Sign up

Export Citation Format

Share Document